New scientific articles

**A multi-centre feasibility study to assess External Quality Assessment panels for Xpert(R) MTB/RIF assay in South Africa.**

**Automated liquid culture system misses isoniazid heteroresistance in Mycobacterium tuberculosis isolates with mutations in the promoter region of the inhA gene.**

**Genotypic susceptibility testing of Mycobacterium tuberculosis for Amikacin and Kanamycin resistance using a rapid Sloppy Molecular Beacon based assay identifies more cases of low level drug resistance than phenotypic Lowenstein-Jensen testing.**

**Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study**

**Prospective Genotyping of Mycobacterium tuberculosis from Fresh Clinical Samples**

**Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in children: a prospective, multi-centre evaluation.**

**Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations.**

**Serum interleukin 6 (IL-6) as a potential biomarker of disease progression in active pulmonary tuberculosis following anti-tuberculosis drug therapy.**

**False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.**

**Role of pre-Xpert® screening using chest X-ray in early diagnosis of smear-negative pulmonary tuberculosis.**

**Novel biomarkers for paediatric tuberculosis.**
Van Rie A, Moultrie H. Lancet Infect Dis. 2014

**Whole-genome sequencing of the Mycobacterium tuberculosis Manila sublineage results in less clustering and better resolution than mycobacterial interspersed repetitive-unit-variable-number tandem-repeat (MIRU-VNTR) typing and spoligotyping.**
The Combined Use of M. tuberculosis-specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis.

How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?

False-negative interferon-γ release assay results in active tuberculosis: a TBNET study.

The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.

Key Publications
Global Tuberculosis Report 2014
GLI training package on Xpert MTB/RIF
High-priority target product profiles for TB diagnostics

Other Publications
Shortening treatment for tuberculosis--to basics.

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.

Short-course Bangladesh regimen for multidrug-resistant tuberculosis: a step in the right direction?
Lalloo UG. Int J Tuberc Lung Dis. 2014

News
Global epidemic of diabetes threatens progress in TB control
Reflecting on the WHO global TB report 2014